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Background: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in
endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention could aid
in country adoption decisions.
Methods: The impact of RTS,S was assessed in 43 countries using an ensemble of models of Plasmodium
falciparum epidemiology. Informed by the 32 months follow-up data from the phase 3 trial, vaccine effec-
tiveness was evaluated at country levels of malaria parasite prevalence, coverage of control interventions
and immunization. Benefits and costs of the program incremental to routine malaria control were eval-
uated for a four dose schedule: first dose administered at six months, second and third - before 9 months,
and fourth dose at 27 months of age. Sensitivity analyses around vaccine properties, transmission, and
economic inputs were conducted.
Results: If implemented in all 43 countries the vaccine has the potential to avert 123 (117;129) million
malaria episodes over the first 10 years. Burden averted averages 18,413 (range of country median esti-
mates 156–40,054) DALYs per 100,000 fully vaccinated children with much variation across settings pri-
marily driven by differences in transmission intensity. At a price of $5 per dose program costs average
$39.8 per fully vaccinated child with a median cost-effectiveness ratio of $188 (range $78–$22,448)
per DALY averted; the ratio is lower by one third - $136 (range $116–$220) - in settings where parasite
prevalence in children aged 2–10 years is at or above 10%.
Conclusion: RTS,S/AS01 has the potential to substantially reduce malaria burden in children across Africa.
Conditional on assumptions on price, coverage, and vaccine properties, adding RTS,S to routine malaria
control interventions would be highly cost-effective. Implementation decisions will need to further con-
sider feasibility of scaling up existing control programs, and operational constraints in reaching children
at risk with the schedule.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction schedule to the target age group and to assess vaccine’s impactWith its safety and efficacy upheld in the phase 3 trial [1,2] and
a positive scientific opinion issued by the European Medicines
Agency [3], the RTS,S/AS01 malaria vaccine is closer to domestic
licensure and implementation in endemic Africa. A global recom-
mendation with respect to vaccine use has been issued by the
WHO [4]. It argues for pilot implementation in distinct epidemio-
logical settings to demonstrate feasibility of delivering theon mortality and potential adverse effects. The recommendation
has been informed with modelled estimates of vaccine’s impact
and cost-effectiveness in generic prevalence settings [5]. Relevance
of these predictions to endemic countries requires further evalua-
tion of the vaccine given geographic specific distribution of malaria
exposure, coverage of preventive and control interventions and
their dynamics, as well as cost of care in these specific settings.
Countries might be interested in these data and explorations of
predictions of vaccine impact taking into account local contexts
before engaging in a considered effort identifying and testing
strategies to deploy this new intervention.
Stochastic models of malaria epidemiology have previously
been used to predict the likely epidemiological impact [6–8] and
54 K. Galactionova et al. / Vaccine 35 (2017) 53–60cost-effectiveness [5,9] of pre-erythrocytic vaccines against Plas-
modium falciparum. These studies indicate that both the disease
burden averted and the cost-effectiveness will be highly depen-
dent on transmission intensity and on vaccine properties including
the decay rate of the vaccine effect, and the degree of homogeneity
in host response. Recent data make it necessary to revise these pre-
dictions. Plasmodium falciparum transmission has decreased dra-
matically over the last decade owing to scale-up of control
interventions and roll-out of artemisinin combination therapy;
infection prevalence in endemic Africa halved and incidence of
clinical disease fell by 40% between 2000 and 2015 [10]. Updated
distributions of malaria exposure that capture these trends along
with the methodology to translate them for inputs into models
for geographic locations have only recently become available
[10,11]. With the release of the final phase 3 data in 2015 the vac-
cine properties can now be determined with greater confidence.
These data suggest that the initial efficacy against infection of
RTS,S is higher but that the effect decays more rapidly, than was
previously estimated from phase 2 and from the shorter follow-
up from phase 3 [12,13].
Using the most recent phase 3 data, a series of new methodolo-
gies [6,11,14,15] are applied to obtain predictions of the likely pub-
lic health impact and cost-effectiveness of RTS,S administered in a
four dose schedule starting at six month. We predict at national
level for each of the 43 endemic Sub-Saharan African (SSA) coun-
tries and avoid speculative choice on geographic areas for pilot
studies or sub-national implementation. In contrast to a recent
study [5], our geographic specific predictions allow for differences
in epidemiological context and health systems across settings, thus
the generated predictions are apt to inform policy decision-making
for malaria control in those settings.2. Methods
2.1. Intervention
The RTS,S vaccine prevents infection by inducing humoral and
cellular immunity, with high antibody titers, that block the para-
site from infecting the liver [16]. It is a monovalent lyophilized vac-
cine reconstituted with an adjuvant (AS01); both require cold
chain storage [17]. Trial data showed the vaccine to be more effica-
cious and enabling protection against severe disease only when
administered in a four dose schedule in children [2]. Mapping trial
design into the routine immunization schedule representative of
SSA suggests a program targeting children between six and nine
months with three doses and an additional fourth dose adminis-
tered 18 months after the third. This schedule aligns with routinely
administered vitamin A supplementation at six months and
measles containing vaccine at nine months, reducing the number
of new visits to only two in countries where these interventions
already exist.
Our assumptions on coverage adjust for the challenges of
scaling-up new interventions and those of reaching children out-
side of routine schedule: 75% of the country Diphtheria-Tetanus-
Pertussis (DTP) rate was taken for the primary schedule, a 20 per-
centage point drop-off was assumed between third and fourth
doses consistent with observed drop-off for measles vaccination
[18]. The vaccine is assumed to be rolled-out through routine out-
lets and to achieve projected coverage within the first year of
implementation.2.2. Vaccine protection against infection
Vaccine profiles were parameterized with data from the
32 month or longer follow-up of the phase 3 clinical trial of RTS,S/AS01 [1]. Vaccine efficacy profiles were estimated by Bayesian
MCMC fitting of model predictions to the site-and time-specific
incidence of clinical malaria in both trial arms over the follow-up
[12]. For the primary schedule, the initial efficacy against infection
at third dose was estimated at 911% with a half-life of 732 months
(with non-exponential decay); the initial efficacy at fourth dose
reached only 49% [12].2.3. Estimating the public health impact of RTS,S immunization
Using a micro-simulation model of malaria epidemiology and
control [19,20], disease burden was predicted for a range of immu-
nization schedules, vaccine properties, entomological inoculation
rates (EIR), and levels of treatment both in the absence and with
the addition of the vaccine. Impact estimates were then computed
as weighted averages over all simulations with weights dependent
on country levels of treatment, coverage, and exposure [6]. PfPR2–10
distributions in 2014 for each country were taken from [10] and
treatment rates - from a previous analysis [14]. Assumptions on
coverage of control interventions including LLINs reflect those
underlying MAP 2014 prevalence surface estimates. Produced by
the Oxford group [10] coverage of control interventions (ITNs,
ACTs, IRS) for the region is estimated with a spatiotemporal Baye-
sian geostatistical model that draws on national malaria control
program and household survey data. The level of malaria preva-
lence (measured by patent parasitemia in children between ages
2 and 10 (PfPR2–10)), control interventions, immunization rate,
population growth, and demography were held constant through-
out the evaluation period. Further details on methodology and data
are given in SI p 3.
By relating clinical disease to severe outcomes and death using
historical data, the model enables predictions of vaccine’s impact
for clinical outputs not explicitly measured in the trial, such as
mortality, and under levels of coverage of preventive and control
interventions representative of the endemic Africa [21]. In this
analysis public health impact of the vaccine was expressed in
terms of uncomplicated and severe malaria episodes, deaths, and
disability-adjusted life years (DALYs) [22], enabling comparison
to other malaria interventions and vaccines. DALYs were estimated
based on a comprehensive measure of deaths that included both
direct malaria deaths and deaths due to malaria co-morbidities
[21]. For comparison, estimates based on direct malaria deaths
only were also reported.2.4. Estimating program costs
Vaccine price was assumed to be $5 per dose; thresholds of $2
and $10 per dose were evaluated in the sensitivity analysis consis-
tent with assumptions in [5]. Program costs included service deliv-
ery and direct household expenditures related to vaccination visit.
These were extrapolated from a recent micro-costing study that
estimated prospectively cost of RTS,S introduction in 6 SSA
countries [15]. Costs capture the economic value of the program
and cover activities carried out both in the introductory stage
and routine delivery. Given the broad scope of the analysis country
specific values were not estimated for this study, instead a median
of service delivery costs from [15] was applied to all countries.
Heterogeneity in operational aspects of the program, unit costs,
and use of resources within the EPI across the region, however,
were addressed in the sensitivity analysis by re-estimating
cost-effectiveness ratios over a broad and representative range of
service delivery costs informed by [15].
Total program costs were based on the number of doses in the
schedule, assumed coverage, and the cohort of surviving infants in
each country. Further details in SI p 5.
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Treatment costs savings were estimated by multiplying the
number of cases averted by the vaccine over routine malaria con-
trol with respective cost per case. It included cost of diagnostics,
antimalarial drugs, consumables (syringes, etc.), as well as facility
charges such as labour and overheads, and direct household expen-
ditures related to treatment-seeking. Costs reflect country levels
and patterns in health seeking for malaria, compliance with the
recommended first-line treatment, adherence with the drug regi-
mens [14], and cost of care [23]. Costing methodology is detailed
in SI p 6.2.6. Estimating cost-effectiveness
The impact of the program was evaluated from the societal
perspective; only direct benefits and costs were considered in
this analysis. Cost of the RTS,S immunization program net of treat-
ment cost savings was related to burden averted by the vaccine;
the two outputs were summarized in terms of an incremental
cost-effectiveness ratio (ICER). Unless otherwise noted, cost-
effectiveness ratios are presented without discounting of health
effects and with discounting of costs (3%) [24]; ratios based on
discounted DALYs averted are reported for comparison with
previous analyses.
Program impact and cost-effectiveness were evaluated over a
10 year horizon with an assumed introduction date in 2017.2.7. Sensitivity analysis
We assessed robustness of the impact predictions by varying
key model inputs along their plausible ranges singly and in combi-
nation (SI Table S3). Choice of parameters was informed by anTable 1
Summary of key inputs used for country specific predictions of RTS,S impact and cost-effe
Input PfPR2–10
<5% 5–10%
PfPR2–10 (%)a 2.6 7
[2.0–4.8] [5.1–9.2
EIRb 0.29 1.64
[0.00–104] [0.43–3
Health seeking (%)c 48.3 53.5
[13.0–75.6] [16.0–7
Effective coverage (%)d 31.7 34.4
[7.8–71.3] [8.3–54
Coverage 3rd dose (%)e 63.1 58.6
[31.5–74.0] [34.7–7
Coverage 4th dose (%)f 50.5 46.9
[25.2–59.2] [27.8–5
Cost per uncomplicated case (USD) 3.82 3.49
[1.62–13.19] [0.56–1
Cost per severe case (USD) 102.93 86.98
[40.91–422.59] [36.20–
GDP per capita (USD)g 1648 1697
[133–7411] [267–5
Government health care expenditures per capita (USD) h 113 78
[17–423] [18–26
Total infants (millions) i 7.5 5.3
Total population (millions) j 230.3 145.6
Number of countries 14 7
Estimates represent medians across countries within the group, range (min-max) repor
a Population weighted median PfPR2–10 based on 2014 estimates from MAP [12].
b Population weighted median EIR based on 2014 estimates from MAP [12].
c Author tabulations based on country DHS data, 14 day recall.
d Defined as an expected probability of clinical and parasitological cure for an episod
e Projected from country DTP coverage [19] assumed 75% of country DTP3 coverage.
f Projected from country DTP coverage [19] assumed 60% of country DTP3 coverage.
g,h,i,j [38]; Country estimates are reported in SI Table S4.earlier extensive analysis of uncertainties around RTS,S predictions
[25] that identified malaria transmission, price, and vaccine prop-
erties as key drivers. Further, multivariate scenarios were defined
to capture the higher ranges of ICERs under conservative assump-
tions about vaccine properties, coverage, and transmission. Broad
ranges over which parameters were varied were chosen to inform
our understanding of the direction and magnitude of the potential
bias in impact estimates induced by uncertainty around these key
inputs at the country level.3. Results
3.1. Overview of transmission, health system, economic, and
demographic inputs
PfPR2–10 averages about 15% across the continent with an equal
number of countries with parasite prevalence below and above
10%; weighted average PfPR2–10 is above 40% only in Guinea and
Mali (Tables 1 and S4). Coverage and effectiveness of malaria case
management is highest in settings with higher transmission inten-
sity; however, the immunization rate appears to be substantially
lower in medium compared to low PfPR2–10 countries. Treatment
health savings only marginally offset the cost of the RTS,S program;
with about half of fevers treated and cost of care significantly
below cost per FVC even at conservative price assumptions. There
is much variation across these key inputs within the narrow trans-
mission ranges; differences that help explain variation in predicted
effectiveness and cost-effectiveness of the vaccine across countries.
3.2. Public health impact and cost-effectiveness of RTS,S immunization
Across the 43 countries the program is estimated to avert over
123 million malaria episodes and over half a million malariactiveness grouped by levels of PfPR2–10 and Gavi eligibility status.
GAVI eligible
(GNI<$1580)
All countries
10–40% >40%
23.3 43.8 15.7 14.8
] [10.7–39.9] [42.2–45.5] [2.0–45.5] [2.0–45.5]
5.27 6.68 3.27 3.12
.53] [0.18–17.38] [6.56–6.81] [0.01–17.38] [0.00–17.38]
61.9 44.1 51.8 55.3
7.3] [32.0–84.0] [40.2–48.1] [13.0–84.0] [13.0–84.0]
36.4 20.6 30.6 33.8
.3] [16.7–65.9] [19.9–21.3] [7.8–65.9] [7.8–71.3]
55.9 49.1 58.4 58.4
2.0] [11.8–70.0] [44.3–54.0] [29.2–74.0] [11.8–74.0]
44.7 39.3 46.8 46.7
7.6] [9.4–56.0] [35.4–43.2] [23.4–59.2] [9.4–59.2]
4.04 1.45 2.18 3.76
0.01] [1.08–22.70] [1.31–1.59] [0.56–4.02] [0.56–22.70]
179.84 45.95 54.24 133.46
238.78] [37.07–1884.67] [45.36–46.54] [36.20–86.90] [36.20–1884.67]
2528 629 744 2018
783] [237–20,581] [531–726] [133–1610] [133–20,581]
113 39 44 103
7] [13–714] [25–53] [13–110] [13–714]
18.9 1.1 22.1 32.8
500.3 27.8 610.8 904.0
20 2 32 43
ted in parenthesis below; Nominal values are expressed in 2013 USD.
e of malaria fever. Updated country estimates based on [15].
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Countries with higher levels of PfPR2–10will benefit most from
the vaccine introduction. At these higher PfPR2–10 ranges, vaccine’s
impact averages over 26,000 DALYs and about 500 deaths averted
per 100,000 FVC; the impact is half as large when estimated across
countries with PfPR2–10 between 5 and 10%, and about a quarter -
in countries with prevalence below 5%. Half of the total predicted
impact of RTS,S vaccination will be incurred in four countries:
Nigeria, Democratic Republic of the Congo, Uganda, and Tanzania;
Nigeria alone accounts for over 20% of total DALYs averted (SI
Fig. S1).
Predicted cost-effectiveness ratios vary similarly with PfPR2–10:
at a vaccine price per dose of $5 the ICER averages $188 (range of
country median estimates 78–22,448) per DALY averted across the
43 countries. The range is widened substantially by a handful of
countries with low PfPR2–10 including Botswana, Djibouti, Eritrea,
and Ethiopia where predicted impact is highly imprecise. When
averaged across countries with PfPR2–10 above 10% the estimated
ICER is about $136 per DALY averted with a much more narrow
range between $115 and $220.
The impact of the vaccine increases with PfPR2–10 and generally
plateaus between PfPR2–10 10 and 40% (Fig. 1). While impact esti-
mates are always positive, the uncertainty around them is large.
It reflects both structural and stochastic uncertainty in the mod-
elled estimates. Variation in the vaccine’s impact and cost-
effectiveness between countries within the narrow transmission
ranges is due to epidemiological and health systems factors; their
role can be illustrated by examining predictions for Gabon and
Niger-countries with the same estimated weighted PfPR2–10 of
15%. Compared to Gabon, the immunization rate in Niger is lower,
and so is the risk and distribution of P. falciparum, all resulting in a
projected impact of the vaccine of about 20% lower and an ICERTable 2
Cumulative predictive impact and cost-effectiveness of RTS,S immunization: disease avert
and GAVI eligibility status.
PfPR2–10
<5% 5–10%
Total episodes averted (millions) 7 21.8
(6.5;7.5) (20.3;23.3)
Total deaths a averted (thousands) 36 106.2
(32.3;39.7) (96.3;116.1)
Total direct deaths b averted (thousands) 20.5 56.3
(18.4;22.6) (50.9;61.7)
Total DALYs averted (millions) 1.9 5.6
(1.7;2.1) (5.1;6.1)
DALYs averted/100,000 FVC 6006 15,289
[156–26,135] [4822–36,946]
Deaths averted/100,000 FVC 115 291
[3–500] [92–703]
Total net program costs (millions)c 1396 1198
(1395;1396) (1197;1199)
$/DALY averted 581 226
[133–22,448] [93–723]
$/Direct DALY averted 994 407
[271–67,529] [174–1678]
$/Discounted DALY averted 1140 444
[262–43,601] [182–1419]
$/Discounted direct DALY averted 1937 797
[532–133,830] [342–3292]
Group totals for events averted and program costs are reported as averages and 95th pe
respective group. Narrow prediction intervals on totals do not imply high precision of
summing country predictions by model and stochastic seed. See SI File 1 for further detail
are reported as medians and min and max range of country median estimates average
estimated without age-weighting and discounting.
a ‘‘Total deaths” inlcude malaria deaths attributable to malaria and deaths that occur
b ‘‘Total direct deaths” inlcude only deaths directly attributable to malaria.
c ‘‘Total net program costs” represent cumulative program costs minus any health sav
systems and patients; costs are discounted at 3%. Total net program costs and ICER’s est
expressed in 2013 USD.twice as high (Tables S4 and S6). On average, however, the ratio
is fairly similar with predicted median ICERs below $200 per DALY
averted across countries with PfPR2–10 above 10%.
Predicted impact is highest in Central African Republic and a
group of coastal West African countries, where over 500 deaths
averted per 100,000 FVC are estimated compared to an average
of about 350 for the region (Fig. 2). Lowest impact is predicted
for countries at the Horn of Africa. It is in these low prevalence set-
tings, including Ethiopia, Eritrea, and Djibouti that the ICERs are
also highest (Table S6).
3.3. Sensitivity analysis
Over the ranges tested and when varied singly parameter
uncertainty translates in predicted ICER and DALY ranges that
are on average, at most, double or half the baseline values
(Fig. 3). There is more heterogeneity across countries in response
to varying parameters related to transmission (scenarios 1, 2)
and immunization coverage (scenarios 3, 19). Small changes in
these inputs result in disproportionally large changes in predic-
tions in lower PfPR2–10 settings. The largest increase in the ICER
is estimated for scenarios 5 and 20. In the prior the vaccine price
per dose is set to $10-twice the baseline assumption- resulting in
predicted ICERs that are also doubled. In the latter, the vaccine is
evaluated under low assumptions on efficacy, half-life, and cover-
age; here again the predicted ICERs double.
4. Discussion
Following 10 years of implementation, RTS,S/AS01 is predicted
to substantially reduce malaria burden in children across endemic
countries in SSA. Consistent with the predictions of a recent multi-ed, costs of the program, and cost-effectiveness grouped by country levels of PfPR2–10
GAVI eligible All countries
10–40% >40%
89.3 5.1 81.3 123.2
(85.3;93.3) (5.0;5.3) (77.4;85.3) (117.3;129.1)
443.9 28.1 404.2 614.2
(415.1;472.8) (26.5;29.6) (375.7;432.6) (571.7;656.8)
221 13.5 206.1 311.2
(205.7;236.3) (12.6;14.3) (190.7;221.4) (288.4;334.0)
23.4 1.5 21.2 32.3
(21.8;24.9) (1.4;1.6) (19.7;22.7) (30.0;34.5)
25,949 28,402 18,050 18,413
[8937–40,054] [17,730–36,008] [156–40,054] [156–40,054]
495 540 345 350
[170–761] [337–682] [3–761] [3–761]
3329 189 4309 6111
(3327;3331) (189;189) (4307;4310) (6108;6114)
132 122 192 188
[78–387] [96–196] [87–22,448] [78–22,448]
267 261 369 360
[147–763] [182–358] [161–67,529] [147–67,529]
260 241 378 370
[154–759] [190–385] [171–43,601] [154–43,601]
525 514 725 707
[288–1492] [358–704] [316–133,830] [288–133,830]
rcentile prediction intervals cumulated over 10 years and over all countries in the
these estimates but rather are an artifact of variation being ‘‘cancelled out” when
s. Cumulative program output metrics per 100,000 FVC and cost-effectiveness ratios
d over uncertainty predictions from the model. Unless otherwise noted DALYs are
with a co-morbidity and malaria.
ings resulting from averted malaria mortality and morbidity incurred by the health
imated from health systems perspective are reported in SI Table S7. Nominal values
Fig. 1. Cumulative predicted impact and cost-effectiveness of RTS,S immunization by PfPR2–10. Predicted impact of the vaccine summarized in terms of DALYs averted per
100,000 FVC (A) and cost per DALY averted (B) are plotted against PfPR2–10 with data points proportional to immunization coverage. Estimates represent country cumulative
statistics averaged across the uncertainty predictions from the model and are overlaid with 95th percentile prediction intervals. Four countries with extremely high cost per
DALY averted were omitted from the plot for ease of viewing. These inlcude countries with very low weighted PfPR2–10 for which model estimates are highly uncertain,
namely Botswana ($1389(208; 12,519)), Djibouti ($1858(877;3696)), Eritrea ($3252(1522;4532)), and Ethiopia ($12,764(3427;22,448)). Median and 95th percentile
prediction intervals across the 39 countries are plotted in pink.
K. Galactionova et al. / Vaccine 35 (2017) 53–60 57model study [5], higher impact is expected in counties with higher
PfPR2–10, and thus higher burden for RTS,S to avert. Country level
estimates, however, differ in magnitude from the corresponding
generic prevalence predictions in [5]. Local estimates reflect differ-
ences in assumptions on vaccination coverage (country range
between 9 and 59% at fourth dose assumed in this study compared
to 72% in [5]), exposure heterogeneity (not explored in ([5]), case
management (country range between 8 and 71% compared to
45% in [5]), and country costs, including service delivery (only cost
of commodities were included in [5]). We show that country speci-
fic epidemiological and health systems factors result in substantial
variation around generic prevalence averages in both public health
impact and cost-effectiveness estimates.
RTS,S is predicted to be highly cost-effective in most countries;
the estimated ICERs are significantly below the regional GDP per
capita (median $842, IQR: $531–$1668) [26,27]. Affordability of
this new intervention, however, is to be further assessed against
program financing and budgets for other vaccines as well as
broader resources for health. Direct comparisons of the vaccine
with other malaria control interventions were not undertaken in
this evaluation. Drawing on literature to provide indicative ranges
for comparison is subject to a number of limitations including dif-
ferences in methodological approaches, scope of costs and effects
considered, scale of the program, relevance of operational aspects
of the program to a particular setting, as well as transmission
effects [28,29]. The importance of the latter is particularly well
illustrated by the large differentials in the vaccine’s predicted
impact and cost-effectiveness across the transmission ranges,
variation that has been documented for other malaria control
interventions as well [29,30]. Ranges of cost-effectiveness from
the literature suggest the vaccine might be more expensive than
current means of malaria control [29] and some of the new vacci-
nes being added to EPI schedules in the region [31–34]. However,
incremental analyses that consider a control intervention package,
including this new intervention, might be more favorable for the
vaccine if effectiveness is evaluated in the same transmission
intensity and scale-up beyond current levels of control programs
is properly accounted for [28].As with all modelling and simulation studies there are a number
of limitations to our analysis. Firstly, predicted vaccine impact is
dependent on the extent of follow-up of immunized children in
the trial and if further follow-up data becomes available it will
be important to reassess the underlying protection of the vaccine.
Secondly, as indicated in a previous analysis [5], predictions of
deaths and thus DALYs averted are dependent on the simulation
model fits to historical data of clinical incidence and mortality.
Results are also dependent on quality of data informing country
levels of current burden, prevalence, immunization coverage, and
demographics. We have attempted to partially address these
uncertainties with sensitivity analysis.
Consistent with previous studies, the level of PfPR2–10 and
heterogeneity in transmission are key drivers of the vaccine’s
impact and cost-effectiveness. Impact estimates presented here,
however, are generated under an assumption of stable transmis-
sion, which implies that there is no additional benefit in terms of
reduction in transmission that could be achieved with current
levels of malaria control. Further, by assuming constant levels of
control interventions the vaccine’s impact may be overstated if
one believes that the recent scale-up of control programs and eco-
nomic development will be sustained into the future [35]. If these
trends are to continue and as malaria intensity subsides, re-
evaluation of vaccine’s viability and cost-effectiveness might be
needed. At low PfPR2–10 (<10%) the vaccine’s impact is predicted
to be modest; here the risk of the disease is shifting to older ages
[36] and the new intervention competes with routine malaria con-
trol for cases to avert. Deployments considering sub-national
implementation targeting pockets of malaria transmission rather
than national campaigns might be more appropriate in these
settings.
Coverage is another key parameter subject to uncertainty; tying
it to routine immunization might have been optimistic given the
vaccine’s properties and short-lived protection it enables. Esti-
mated ICERs increase to $256[$134-$12,528] per DALY averted
when coverage is reduced by 25% (Table S8). Alternatively, if the
program achieves coverage rates similar to country DTP levels,
the ratio decreases to $139[$70-$7047] per DALY averted and in
Fig. 2. Cumulative impact and cost-effectiveness of RTS,S immunization by country. Cumulative number of clinical cases (A), deaths (B), DALYs (C) averted per 100,000 FVC,
and cost per DALY averted (2013 USD) (D) at year 10 following vaccine introduction. Country estimates represent mean values averaged over uncertainty predictions from the
model.
58 K. Galactionova et al. / Vaccine 35 (2017) 53–60settings with PfPR2–10 above 10% it is reduced to $95[$70-$173].
Several studies have been conducted to assess the vaccine’s accept-
ability in endemic countries [37–40]; while community response
has been positive, it is difficult to judge whether it will translate
to as high uptake, particularly as protection begins to wane and
vaccinated children continue to fall ill. Careful and sustained com-
munication will be key to the program’s success.
For an RTS,S program to reach its full potential, it is not only
important to ensure vaccination at rates similar to those achieved
with routine vaccines in the general population but reaching
groups with the highest risk of malaria becomes pivotally
important. Achieving high coverage for these vulnerable children
will require addressing social and cultural perceptions about the
vaccines, improving systems for providing health care, anddevising innovative delivery strategies to reach these generally
underserved populations.
Furthermore, the predictions were made at national levels of
coverage of control interventions and immunization rates; these
do not incorporate inequities in access to health services, particu-
larly with respect to heterogeneity in malaria transmission. Not
only is malaria risk higher among these marginalized groups, but
given lower coverage of control interventions, the outcomes of
malaria episodes are also more severe [41,42]. Policies should thus
consider the operational advantages of targeting these populations
with the vaccine, and the extent to which RTS,S immunization
could be combined with strengthening delivery of other preventive
and control measures, including interventions aimed at health
risks other than malaria.
Fig. 3. Sensitivity analysis over range of vaccine properties and country specific inputs: percent change in predicted ICER and DALYs averted from baseline scenario. Estimates
represent change in predicted DALYs averted and ICER in response to varying single or multiple parameters from baseline to its low and high values (see Appendix Table S3
for ranges simulated). The change in predicted DALYs averted is summarized as a median and a range (min-max) across 43 countries. Values of predicted ICERs and DALYs
averted for each scenario are reported in Appendix Table S7. The following scenarios were simulated: 1 Transmission high; 2 Transmission low; 3 Immunization rate high; 4
Immunization rate low; 5 Price high; 6 Price low; 7 Delivery cost high; 8 Delivery cost low; 9 Discount rate high; 10 Discount rate low; 11 Time horizon high; 12 Time horizon
low; 13 Half-life high; 14 Half-life low; 15 Efficacy high; 16 Efficacy low; 17 Initial efficacy and half-life high; 18 Initial efficacy and half-life low; 19 Initial efficacy, half-life,
and immunization rate high; 20 Initial efficacy, half-life, and immunization rate low.
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Immunization Program (NIP) will have broad implications for the
health systems [43]. It might undermine routine care provision if
resources, including medical staff and cold chain, are diverted
away to accommodate the new intervention. One the other hand,
new vaccination visits provide another opportunity for health pro-
viders to reach children that may lead to improvements in health
beyond malaria related outcomes. Most directly, malaria burden
averted will reduce use of outpatient and, to a lesser extent, inpa-
tient services by children. At assumed coverage rates for the new
program and at current levels of malaria case management a
reduction of 9.14% [1.29–18.86] in visits for uncomplicated malaria
is predicted and 7.06% [0.79–14.84] for severe episodes across the
43 countries (Table S5) - a substantial decrease in service volume.
At the same time introduction of RTS,S will also require signif-
icant resources. Estimates of cost-effectiveness presented in this
analysis rely on generic assumptions about cost of vaccine delivery
and as such do not capture the heterogeneity cost of service deliv-
ery across countries. Yet, at vaccine price of $5 per dose these costs
account for 10–26% of total program costs; the fraction is higher in
settings where cost of labour is high [15]. This suggests that
variation in cost of service delivery, assuming routine deployment,
contributes only marginally to uncertainty in predicted ratios
(Table S8, scenarios 7–8). As ICERs vary almost linearly with price,
estimates can be updated with setting specific information on
cost of service delivery or costs of alternate vaccine deployment
modality if available.
WHO’s recommendation for a large scale trial implementation
of RTS,S targets primarily uncertainties around the operationalaspects of the program, namely the feasibility of delivering a four
dose schedule that includes new immunization visits in a weak
health systems environment [4]. While the details of the program
are best tested in a trial setting, our analysis provides further sup-
port to the recommendation’s focus on ‘‘how best to” introduce the
vaccine. We show that at higher transmission intensities RTS,S
remains highly cost-effective even under most conservative
assumptions on vaccine properties, coverage, and price. Pilot stud-
ies should prioritize deployment modalities that include delivery
of the vaccine along other health services and seek broader syn-
ergies within the National Immunization Program. Our analysis
suggests scope for sub-national implementation in settings with
heterogeneous transmission and highlights the advantages of tar-
geted and outreach strategies to populations at highest risk where
most impact is likely to be achieved. Furthermore, the analysis
offers some initial setting-specific predictions of potential vaccine
impact against which trial results could be scaled to inform coun-
try adoption decisions.Contributors
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